
Lupin Ltd. is Rated Sell by MarketsMOJO
2026-11-13 10:12:22Lupin Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 November 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 13 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read MoreLupin Declines 0.95% Amid Margin Pressures and Mixed Market Signals
2026-11-07 16:06:05Key Events This Week 2 Nov: Stock opens at Rs.1,996.55, declines 0.62% amid Sensex rally 3 Nov: Significant open interest surge in derivatives despite modest price gain 4 Nov: Q2 results reveal strong revenue growth but margin contraction 5 Nov: Stock dips 1.36% on heavy volume amid margin concerns 6 Nov: Week closes at Rs.1,990.00, down 0.31% on the day Week Open<div class="stat-v...
Read More
Lupin Ltd Q2 2026 Results Show Margin Pressure Amid Revenue Growth
2026-11-04 13:00:36Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a marked shift in its financial trajectory during the September 2026 quarter. Despite robust net sales growth, the company’s profitability metrics have deteriorated, prompting a downgrade in its Mojo Grade from Hold to Sell. This article analyses Lupin’s recent quarterly performance in the context of its historical trends and broader market movements.
Read More
Lupin Ltd. Sees Significant Open Interest Surge Amid Mixed Market Signals
2026-11-03 15:00:10Lupin Ltd., a mid-cap pharmaceutical player, has witnessed a notable 11.05% increase in open interest in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite a modest price decline of 0.19% on 3 Nov 2026, the surge in open interest and volume patterns suggest a complex interplay of directional bets and market sentiment within the Pharmaceuticals & Biotechnology sector.
Read More
Lupin Ltd. is Rated Hold by MarketsMOJO
2026-11-02 10:10:02Lupin Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 02 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read MoreLupin Ltd. Declines 1.57% Amid 52-Week Lows and Rising Derivatives Activity
2026-10-24 16:05:13Key Events This Week Oct 19: Stock opens at Rs.1,953.75, marginally down amid broader market weakness Oct 21: Slight recovery to Rs.1,957.00 despite Sensex decline Oct 22: Lupin hits 52-week low of Rs.1,897.25; open interest surges 13.4% Oct 23: New 52-week low of Rs.1,893.25; open interest rises 10.96% Week OpenRs.1,955.80 <div class="stat-label"...
Read More
Lupin Ltd. Sees Sharp Open Interest Surge Amidst Mixed Market Signals
2026-10-23 15:00:35Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased market participation and potential shifts in investor positioning. Despite trading close to its 52-week low, the stock’s derivatives activity suggests evolving directional bets that merit close attention from market participants.
Read More
Lupin Ltd. Sees Significant Open Interest Surge Amidst Market Pressure
2026-10-23 13:00:20Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.9% surge in open interest in its derivatives segment, signalling heightened market activity despite the stock trading near its 52-week low. This development comes amid a backdrop of subdued price performance and declining investor participation, raising questions about evolving market positioning and potential directional bets.
Read More
Lupin Ltd. Sees Significant Open Interest Surge Amid Bearish Price Action
2026-10-22 15:00:31Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a notable 13.4% surge in open interest in its derivatives segment on 22 Oct 2026, despite the stock underperforming the sector and closing near its 52-week low. This divergence between rising open interest and declining price signals evolving market positioning and potential directional bets among traders.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
17-Nov-2026 | Source : BSENewspaper Publication regarding the Notice of Postal Ballot and Remote E-Voting.
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
16-Nov-2026 | Source : BSENotice of Postal Ballot dated November 03 2026 along with Explanatory Statement.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
12-Nov-2026 | Source : BSELupin Announces European Launch of Biosimilar Ranibizumab.
Corporate Actions
No Upcoming Board Meetings
Lupin Ltd. has declared 900% dividend, ex-date: 17 Jul 26
Lupin Ltd. has announced 2:10 stock split, ex-date: 27 Aug 10
Lupin Ltd. has announced 1:1 bonus issue, ex-date: 11 Aug 06
No Rights history available